Editorial Policy

The rules that govern how BalancePhase content is produced, reviewed, corrected and disclosed.

This policy applies to everything published under the BalancePhase name, in every language and every market we cover. Where a specific market imposes stricter requirements, the stricter requirement applies.

Editorial independence

Editorial decisions at BalancePhase are made by the editorial team alone. No advertiser, affiliate partner, manufacturer or distributor has input into:

Commercial partners do not receive advance copies of reviews and are not consulted before publication. Where a partner has raised a factual objection to a published review, we investigate it as we would any factual challenge — on the evidence, not on the relationship.

Commercial relationships

BalancePhase is funded by affiliate commissions. This is disclosed on every page containing affiliate links, in a visible statement at the top of the content, before the reader reaches the review itself.

The full detail of how commissions work, which types exist and what they do not affect is set out in our Affiliate Disclosure. The governing principle is simple: a commission has no effect on an assessment. We publish negative assessments, including explicit recommendations not to purchase, on the same terms as positive ones.

Authorship and responsibility

Every review carries a named editor. BalancePhase content is produced under the editorial direction of W. H. Neves, who is identified on the About page and holds responsibility for the accuracy of what the site publishes.

Where a review involves an area of specialised expertise, that expertise is either present on the editorial team or explicitly declared as absent. We do not attribute medical, pharmaceutical or dietetic credentials to anyone who does not hold them.

Corrections policy

When we get something wrong, we correct it and we say so.

How to submit a correction

Email editorial@balancephase.com with the URL of the article, the specific statement you believe is inaccurate, and whatever evidence supports your position. We acknowledge every correction request.

How corrections are applied

We do not remove articles because a manufacturer or affiliate partner objects to them. Articles are removed only where they should never have been published, in which case a removal notice explaining why is left in their place.

Use of AI in content production

Our position

BalancePhase uses AI tools as part of its production workflow, principally for research assistance, drafting support, translation and structural editing. We state this openly because a publication that conceals its production method is asking readers to trust something they cannot see.

What AI does not do at BalancePhase: it does not make editorial judgements, it does not verify facts on its own authority, and it does not publish anything that has not been checked by the editorial team against primary sources.

In practical terms:

Conflicts of interest

Beyond affiliate commissions, the editorial team is required to disclose any personal or financial interest that could reasonably be seen to affect an assessment — ownership of a relevant business, consultancy work for a manufacturer or retailer, or a material shareholding.

No member of the editorial team reviews a product in which they hold a direct financial interest. Where a potential conflict exists and cannot be avoided, it is disclosed in the article itself.

Sources and citation

Reviews cite their sources. Regulatory positions are linked to the relevant register or guidance document. Research findings are cited to the paper rather than summarised without reference. Where a claim cannot be sourced, we do not make it.

We do not cite studies we have not read, do not attribute findings to a source that does not support them, and do not present a single trial or small study as though it were established consensus.

Language and markets

BalancePhase publishes content for the United States, United Kingdom, Germany and the Netherlands. Content is written for the regulatory framework of each market, not translated mechanically from a single master version. A health claim authorised by EFSA for the EU market is not assumed to be authorised by the FDA for the US market, and our reviews reflect the difference.

Complaints

Complaints about editorial conduct, breaches of this policy, or content you believe is misleading should be sent to editorial@balancephase.com. We respond to all editorial complaints and record how they were resolved.

Related pages

See also: Methodology, Affiliate Disclosure, Privacy Policy, Terms of Use.